Tag #Wegovy

Showing 25 to 36 of 68 results

nos.nl

🌐 85% Global Worthiness

Jun 1, 01:10

UK Obesity Crisis: Weight-Loss Drug Success Creates Dangerous Black Market

In the UK, the rising popularity of GLP-1 weight-loss medication like Wegovy and Ozempic, despite strict NHS access, has created a black market with reports of misuse leading to hospitalizations; while effective for weight loss and related health problems, unregulated access poses serious health ris...

UK Obesity Crisis: Weight-Loss Drug Success Creates Dangerous Black Market

In the UK, the rising popularity of GLP-1 weight-loss medication like Wegovy and Ozempic, despite strict NHS access, has created a black market with reports of misuse leading to hospitalizations; while effective for weight loss and related health problems, unregulated access poses serious health ris...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the existence of a black market for weight-loss medication affect healthcare systems in the UK, particularly concerning patient safety and the appropriate use of these drugs?

The high prevalence of obesity in the UK (one in four with obesity, almost two-thirds overweight) fuels demand for these medications, creating both opportunities and risks. While the drugs show promise in reducing healthcare costs and boosting the economy, the unregulated market poses significant safety concerns.

sante.lefigaro.fr

🌐 75% Global Worthiness

May 26, 22:10

France Expands Access to Anti-Obesity Drugs

The French government will allow general practitioners to prescribe Wegovy and Mounjaro to combat obesity, affecting nearly 50% of French adults; a plan launching in September will address this through education, healthcare, sports, and medication, aiming to curb cardiovascular deaths.

France Expands Access to Anti-Obesity Drugs

The French government will allow general practitioners to prescribe Wegovy and Mounjaro to combat obesity, affecting nearly 50% of French adults; a plan launching in September will address this through education, healthcare, sports, and medication, aiming to curb cardiovascular deaths.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of expanding access to Wegovy and Mounjaro for obesity treatment in France?

The French government plans to expand access to Wegovy and Mounjaro, two anti-obesity medications, by allowing general practitioners to prescribe them. Currently, only endocrinology specialists can prescribe these medications, which cost \$300 per month and are not covered by insurance. This decision aims to address the high prevalence of obesity in France, affecting nearly 50% of adults.

zeit.de

🌐 85% Global Worthiness

May 20, 07:12

Surge in Forged Prescriptions for Weight-Loss Injections

A surge in demand for weight-loss injections like Ozempic and Wegovy has led to a significant increase in forged prescriptions, particularly paper prescriptions, causing financial losses for pharmacies and raising concerns about patient safety.

Surge in Forged Prescriptions for Weight-Loss Injections

A surge in demand for weight-loss injections like Ozempic and Wegovy has led to a significant increase in forged prescriptions, particularly paper prescriptions, causing financial losses for pharmacies and raising concerns about patient safety.

Progress

40% Bias Score

ShareSaveArticle

Reduced Inequality

12345678

Previous 1 of 8 Next

What are the long-term implications of this trend for pharmaceutical security and patient safety?

The widespread use of e-prescriptions could significantly curb prescription forgery. The high price and restricted patient access to these medications, coupled with media attention, further fuel the criminal activity. This trend underscores the need for stronger regulatory measures and public awareness campaigns to combat this issue and protect patient safety.

cnn.com

🌐 85% Global Worthiness

May 16, 19:13

Novo Nordisk CEO Steps Down Amidst Market Challenges and Share Price Plunge

Novo Nordisk CEO Lars Fruergaard Jorgensen resigned Friday due to a 50%+ share price decline since mid-2024, driven by cheaper competitor drugs and a recent head-to-head study showing a competitor's superior efficacy.

Novo Nordisk CEO Steps Down Amidst Market Challenges and Share Price Plunge

Novo Nordisk CEO Lars Fruergaard Jorgensen resigned Friday due to a 50%+ share price decline since mid-2024, driven by cheaper competitor drugs and a recent head-to-head study showing a competitor's superior efficacy.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary cause of Novo Nordisk's recent challenges and the CEO's departure?

Novo Nordisk CEO Lars Fruergaard Jorgensen stepped down due to recent market challenges and a more than 50% decline in the company's share price since mid-2024. This follows a downgraded sales and profit forecast and increased competition from cheaper replica drugs and competitor drug Zepbound.

dailymail.co.uk

🌐 85% Global Worthiness

May 8, 01:17

Novo Nordisk Cuts Forecasts Amid Copycat Weight-Loss Drug Surge

Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, cut its sales and profit forecasts due to competition from copycat weight-loss drugs made by compounding pharmacies in the US, which captured about a third of the market despite a forthcoming ban and the company exceeding first...

Novo Nordisk Cuts Forecasts Amid Copycat Weight-Loss Drug Surge

Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, cut its sales and profit forecasts due to competition from copycat weight-loss drugs made by compounding pharmacies in the US, which captured about a third of the market despite a forthcoming ban and the company exceeding first...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did the US regulatory actions regarding compounding pharmacies contribute to the current market situation for Novo Nordisk's obesity drugs?

The surge in copycat drugs, enabled by US compounding practices, significantly impacted Novo Nordisk's growth in the US, its largest market. Despite increased supplies, US prescriptions haven't grown since February, highlighting the market share taken by compounding pharmacies. This unexpected competition led to a downward revision of Novo's sales and profit forecasts.

cincodias.elpais.com

🌐 75% Global Worthiness

May 2, 10:12

Novo Nordisk's Telemedicine Deal to Counter Eli Lilly in Obesity Drug Market

Novo Nordisk partnered with Hims & Hers Health to sell its Wegovy weight-loss drug through telemedicine platforms at discounted prices, directly competing with Eli Lilly's Zepbound strategy amid insurance coverage challenges and following a recent stock decline of over 30% since January 2025, after ...

Novo Nordisk's Telemedicine Deal to Counter Eli Lilly in Obesity Drug Market

Novo Nordisk partnered with Hims & Hers Health to sell its Wegovy weight-loss drug through telemedicine platforms at discounted prices, directly competing with Eli Lilly's Zepbound strategy amid insurance coverage challenges and following a recent stock decline of over 30% since January 2025, after ...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What immediate impact will Novo Nordisk's telemedicine partnership have on its revenue and market share in the obesity drug sector?

Novo Nordisk, facing investor uncertainty due to concerns about future treatments, announced a new agreement with Hims & Hers Health to sell Wegovy via telemedicine platforms at reduced prices. This follows Eli Lilly's similar strategy with Zepbound, highlighting the growing use of telemedicine to increase sales amid challenges in securing insurance coverage for obesity drugs. This partnership aims to boost revenue and compete with Eli Lilly.

dailymail.co.uk

🌐 75% Global Worthiness

Jun 1, 13:11

Australian Weight Loss Drug Users Report Liver Issues

Dozens of Australians using weight-loss injections Wegovy, Ozempic, and Mounjaro have reported liver problems, including hepatitis, prompting a warning from experts for regular GP check-ups; three cases linked to semaglutide were reported to the TGA.

Australian Weight Loss Drug Users Report Liver Issues

Dozens of Australians using weight-loss injections Wegovy, Ozempic, and Mounjaro have reported liver problems, including hepatitis, prompting a warning from experts for regular GP check-ups; three cases linked to semaglutide were reported to the TGA.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What specific actions should patients taking GLP-1 agonist weight-loss injections take to minimize liver-related risks?

Dozens of Australians using weight-loss injections like Wegovy, Ozempic, and Mounjaro have reported liver-related issues, including hepatitis. Three cases linked to semaglutide (Ozempic and Wegovy) have been reported to the TGA, prompting warnings for regular GP check-ups. Patients experienced flu-like symptoms, fatigue, and abdominal pain.

cbsnews.com

🌐 85% Global Worthiness

May 23, 01:12

GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk

A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.

GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk

A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the observed effects of GLP-1 agonists on cancer risk compare between men and women, and what factors might explain these differences?

This research connects the weight-loss effects of GLP-1 agonists to a potential reduction in obesity-related cancer risk. The 8% lower risk of all-cause mortality observed in women highlights the potential broader health benefits beyond weight management. This observational study indicates a potential preventative role, but further research is needed to confirm causality and expand to non-diabetic populations.

sueddeutsche.de

🌐 85% Global Worthiness

May 20, 07:12

Forgery of Weight-Loss Drug Prescriptions on the Rise

The surge in demand for weight-loss injections like "Ozempic" and "Wegovy" has led to prescription forgeries, primarily targeting paper prescriptions, with criminals, often from Eastern Europe, creating fake prescriptions to obtain these high-priced drugs. This results in substantial financial losse...

Forgery of Weight-Loss Drug Prescriptions on the Rise

The surge in demand for weight-loss injections like "Ozempic" and "Wegovy" has led to prescription forgeries, primarily targeting paper prescriptions, with criminals, often from Eastern Europe, creating fake prescriptions to obtain these high-priced drugs. This results in substantial financial losse...

Progress

36% Bias Score

ShareSaveArticle

Reduced Inequality

12345678

Previous 1 of 8 Next

How do the characteristics of "Ozempic" and "Wegovy" (high price, limited access) contribute to the rise in prescription fraud?

Increased demand fueled by media coverage and celebrity endorsements, coupled with restricted patient access and high drug prices, has created a lucrative market for counterfeit weight-loss medications. The ease of forging paper prescriptions, compared to electronic ones, contributes to the problem.

theglobeandmail.com

🌐 85% Global Worthiness

May 16, 16:10

Novo Nordisk CEO Steps Down Amidst Market Challenges and Competition

Novo Nordisk CEO Lars Fruergaard Jorgensen resigned Friday due to market challenges and declining share prices after Eli Lilly's Zepbound surpassed Wegovy in US prescriptions since mid-March; former CEO Lars Rebien Sorensen will join the board as an observer.

Novo Nordisk CEO Steps Down Amidst Market Challenges and Competition

Novo Nordisk CEO Lars Fruergaard Jorgensen resigned Friday due to market challenges and declining share prices after Eli Lilly's Zepbound surpassed Wegovy in US prescriptions since mid-March; former CEO Lars Rebien Sorensen will join the board as an observer.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary reason for Novo Nordisk's CEO stepping down, and what are the immediate consequences for the company?

Novo Nordisk CEO Lars Fruergaard Jorgensen stepped down due to market challenges and declining share price. Eli Lilly's obesity drug Zepbound surpassed Wegovy in US prescriptions since mid-March, impacting Novo Nordisk's market share. The company's share price is down 32% year-to-date and 59% from its all-time high.

news.sky.com

🌐 85% Global Worthiness

May 2, 07:16

Weight Loss Injections: Pharmacy Access Planned

A potential multimillion-pound deal could allow pharmacies in England to offer weight loss injections like Ozempic and Wegovy for £9.90 after a short consultation, addressing current NHS limitations and long wait times.

Weight Loss Injections: Pharmacy Access Planned

A potential multimillion-pound deal could allow pharmacies in England to offer weight loss injections like Ozempic and Wegovy for £9.90 after a short consultation, addressing current NHS limitations and long wait times.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of making weight-loss injections available over the counter in pharmacies?

Pharmacies in England may soon offer weight-loss injections like Ozempic and Wegovy after a short consultation, costing £9.90. This follows reports of a multimillion-pound deal for a pilot program to increase access, currently limited by a two-year waiting list on the NHS and a postcode lottery.

nbcnews.com

🌐 90% Global Worthiness

May 1, 01:17

Wegovy Shows Promise in Treating Serious Liver Disease

A Novo Nordisk-funded trial shows Wegovy effectively treated MASH in 63% of 800 patients across 37 countries, significantly improving liver inflammation and fibrosis, leading to potential FDA approval by year-end.

Wegovy Shows Promise in Treating Serious Liver Disease

A Novo Nordisk-funded trial shows Wegovy effectively treated MASH in 63% of 800 patients across 37 countries, significantly improving liver inflammation and fibrosis, leading to potential FDA approval by year-end.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the long-term implications of Wegovy's efficacy in treating MASH, including the potential for relapse, durability of effects, and the need for continued medication?

The FDA's priority review of Wegovy for MASH, with a decision expected by year's end, signifies a potential paradigm shift in treating this prevalent liver disease. However, long-term studies are crucial to assess the durability of these improvements and determine whether the treatment translates to reduced long-term liver complications and mortality. The cost and potential side effects, primarily gastrointestinal issues, also warrant careful consideration.

Showing 25 to 36 of 68 results